Linalool targets NR3C2 to inhibit NF-κB-mediated gastric cancer progression

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gastric cancer (GC) presents a significant global health burden.
• Understanding novel therapeutic targets and mechanisms is crucial for effective GC treatment.

Purpose of the Study:

• To investigate the anti-gastric cancer efficacy of linalool.
• To elucidate the molecular mechanisms underlying linalool's action in GC.
• To explore the role of NR3C2 and NFKBIZ in GC progression and their correlation with clinical features.

Main Methods:

• In vitro studies using GC cell lines to assess proliferation, migration, and invasion.
• In vivo experiments using nude mice with transplanted tumors.
• Protein interaction and degradation assays (e.g., proteasomal degradation).
• Gene expression analysis (transcriptional activation) and functional rescue experiments.
• Analysis of clinical GC samples for protein/gene expression and correlation with pathological staging.

Main Results:

• Linalool inhibited GC cell proliferation, migration, invasion, and reduced transplanted tumor growth.
• Linalool stabilized NR3C2 protein by preventing its proteasomal degradation.
• NR3C2 knockdown partially reversed linalool's anti-tumor effects.
• NR3C2 transcriptionally activated NFKBIZ, which inhibited NF-κB signaling.
• Restoring NFKBIZ expression counteracted GC progression due to NR3C2 deficiency.
• Lower NR3C2 and NFKBIZ expression in GC tissues correlated with advanced T and pTNM stages.
• Low NR3C2/NFKBIZ expression was linked to activated NF-κB signaling and increased inflammatory cytokines.

Conclusions:

• Linalool exerts anti-gastric cancer effects by upregulating NR3C2 and subsequently NFKBIZ, leading to NF-κB signaling suppression.
• The NR3C2-NFKBIZ axis represents a critical pathway in GC progression.
• Low expression of NR3C2 and NFKBIZ serves as a potential biomarker for adverse clinical outcomes in gastric cancer.